Where can researchers source third-party tested VIP?

Midwest Peptide supplies research-grade VIP with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

VIP Immune Modulation Research | Midwest Peptide

Peptide Research Design: In Vivo Study FundamentalsPrev|Where to Buy the KLOW Peptide Blend for Research: Multi-Peptide Sourcing GuideNext

VIP Immune Modulation Research: T-Cell and Macrophage Literature

Q: Is VIP approved for human use?

No. VIP is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

VIP · Published April 14, 2026 · Updated May 18, 2026 · 7 min read

Quick Answer

VIP immune modulation research examines T cell and macrophage effects in rodent immune research models. Studies measure cytokine production, immune cell polarization, and VPAC receptor-mediated immune biomarkers across standardized immunomodulation research protocols using vasoactive intestinal peptide. For research use only, not for human consumption.

VIP Immune Modulation Research: T-Cell and Macrophage Literature

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

VPAC Receptor Expression on Immune Cells
T Cell Research
Macrophage and Dendritic Cell Research
Autoimmune Disease Model Research
Inflammatory Cytokine Research
Clinical Research Context
Relationship to Other Immune Research Peptides
Research Peptide Referenced
Related Research Reading
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

VIP immune modulation research extends the VIP research cluster from the vascular and neural biology covered elsewhere in the cluster into the immune system, where VPAC receptor expression on lymphocytes and macrophages supports a significant body of research literature on immunomodulatory effects of the peptide.

Frequently Asked Questions

What is VIP in research contexts?

VIP (vasoactive intestinal peptide) is an endogenous 28-amino-acid neuropeptide of the secretin/glucagon superfamily. It is studied in preclinical models for vasodilation, immune modulation, circadian rhythm regulation, and pulmonary smooth muscle research through VPAC1 and VPAC2 receptor signaling.

How does VIP modulate immune function?

VIP shifts T cell responses toward T helper 2 (Th2) and regulatory T cell (Treg) phenotypes, modulates macrophage polarization toward M2 anti-inflammatory state, and reduces pro-inflammatory cytokine production. These effects support an integrated anti-inflammatory profile in research models.

What immune endpoints are measured with VIP?

Endpoints include T cell subset analysis (Th1/Th2/Th17/Treg), cytokine profiles, macrophage polarization markers, dendritic cell function, and integrated assessment in autoimmune models including experimental autoimmune encephalomyelitis (EAE), arthritis, and colitis.

Is VIP approved for human use?

Glossary

Key terms used in this article.

VPAC1: Vasoactive intestinal peptide receptor 1, broadly distributed, mediating immune and gastrointestinal effects of VIP.
VPAC2: Vasoactive intestinal peptide receptor 2, enriched in the suprachiasmatic nucleus and lung, involved in circadian and pulmonary signaling.
Suprachiasmatic Nucleus (SCN): The hypothalamic master circadian pacemaker, where VPAC2 signaling is essential for synchronizing rhythmic neuronal activity.
Vasodilation: Widening of blood vessels resulting from relaxation of vascular smooth muscle, often mediated by nitric oxide or VIP signaling.
Neuropeptide: A peptide produced and released by neurons that acts as a signaling molecule in the nervous system.
Treg: Regulatory T cell, a CD4+ T cell subset that suppresses immune responses, expanded by VIP signaling.
EAE: Experimental autoimmune encephalomyelitis, a rodent model of multiple sclerosis used to study CNS autoimmunity.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. VIP is intended strictly for in vitro and preclinical animal research. It is not approved for human use, is not a drug, and should never be administered to humans.

VPAC Receptor Expression on Immune Cells

The VPAC1 and VPAC2 receptors are expressed on multiple immune cell populations including T lymphocytes, B lymphocytes, macrophages, dendritic cells, and mast cells. The specific receptor expression pattern differs across cell types, with T cells typically expressing more VPAC1 and macrophages expressing both VPAC1 and VPAC2 at varying levels depending on activation state. The integrated receptor biology is covered in the VPAC receptor research article in this cluster.

VPAC receptor signaling on immune cells produces shifts in functional phenotype that are generally toward less inflammatory and more regulatory profiles. T cells shift toward Th2 and regulatory T cell differentiation at the expense of Th1 differentiation. Macrophages shift toward the M2 anti inflammatory polarization and away from the M1 pro inflammatory polarization. Dendritic cells take on tolerogenic rather than immunogenic properties. The integrated effect is a broad anti inflammatory modulation of immune function.

The Nature subject hub on immune regulation archives primary research on the intracellular signaling pathways that mediate these effects. The Cell Press journal Cell Reports Medicine and the ScienceDirect immune regulation topic page provide additional entry points into the primary literature.

T Cell Research

T cell responses to VIP have been characterized in detail in cell culture systems and in rodent models. Published findings document that VIP exposure during T cell activation shifts the cytokine profile away from interferon gamma production and toward interleukin 4 and interleukin 10 production. This cytokine shift represents the Th1 to Th2 skewing that is one of the classical immunomodulatory effects of VIP.

Regulatory T cell research has documented that VIP supports the differentiation of naive CD4 T cells into Foxp3 positive regulatory T cells under defined culture conditions. The resulting regulatory T cells have suppressive function in in vitro assays and can suppress autoimmune responses in rodent adoptive transfer models. These findings position VIP as a research tool for studies on regulatory T cell biology and on immune tolerance.

The cellular mechanism involves VPAC receptor activation, increased cyclic AMP, and protein kinase A mediated modulation of transcription factors including NFAT, NF kB, and Foxp3. The transcription factor modulation produces the phenotypic shifts observed in cytokine production and in transcription factor expression.

Macrophage and Dendritic Cell Research

Macrophage polarization between the M1 pro inflammatory and M2 anti inflammatory states is a core concept in macrophage biology. Published VIP research in cultured macrophage preparations documents shifts toward M2 polarization, with increased expression of M2 associated genes and decreased expression of M1 associated genes. The functional consequences include reduced production of pro inflammatory cytokines including tumor necrosis factor and interleukin 6, reduced reactive oxygen species generation in response to stimulation, and enhanced resolution of inflammatory responses.

Dendritic cell research has documented similar anti inflammatory shifts. VIP exposure during dendritic cell maturation produces cells with reduced expression of co stimulatory molecules, reduced production of pro inflammatory cytokines, and enhanced production of interleukin 10. These properties favor the development of T cell tolerance rather than T cell activation when the dendritic cells present antigen. The tolerogenic dendritic cell phenotype is of substantial research interest in autoimmune disease research and transplantation research.

The Wiley Online Library immunology collection and the Frontiers in Immunology open access journal both archive primary research on macrophage polarization and dendritic cell biology that provides useful context.

Autoimmune Disease Model Research

Rodent models of autoimmune disease provide research contexts for examining the integrated immunomodulatory effects of VIP. Experimental autoimmune encephalomyelitis models Th1 mediated central nervous system autoimmunity. Collagen induced arthritis models Th17 mediated joint autoimmunity. Inflammatory bowel disease models including DSS induced colitis model Th1 and Th17 mediated gut inflammation. VIP has been examined in each of these model systems with findings of reduced disease severity and improved histological endpoints in treated animals.

The mechanistic interpretation integrates the T cell, macrophage, and dendritic cell effects described above. The shift toward regulatory and anti inflammatory immune phenotypes produces reduced effector immune activity at the tissue level, which translates into reduced autoimmune damage in the model systems. The integrated effect across multiple immune cell types is generally larger than what isolated effects on any single cell type would produce.

The research on VIP in autoimmune disease models connects to the VIP neuroinflammation research covered in this cluster, which addresses specifically the central nervous system inflammatory component. The integrated view is that VIP has broad anti inflammatory activity that operates through modulation of multiple immune cell populations, and that this activity has implications for research across many inflammatory disease models.

Inflammatory Cytokine Research

Direct measurement of inflammatory cytokine profiles under VIP administration has been performed in rodent models and in cultured immune cell systems. The findings document reductions in pro inflammatory cytokines including tumor necrosis factor, interleukin 1 beta, interleukin 6, and interferon gamma. Parallel increases in anti inflammatory cytokines including interleukin 10 and transforming growth factor beta have been documented.

The cytokine profile shifts reflect the integrated effects on the immune cell populations that produce each cytokine. Pro inflammatory cytokines are primarily produced by Th1 T cells, M1 macrophages, and mature dendritic cells, all of which are suppressed by VIP. Anti inflammatory cytokines are primarily produced by regulatory T cells, M2 macrophages, and tolerogenic dendritic cells, all of which are supported by VIP. The coordinated cytokine shift is consistent with the cellular level findings.

Age Verification

VIP Immune Modulation Research: T-Cell and Macrophage Literature